Last reviewed · How we verify

Pseudoephedrine/Paracetamol

McNeil AB · FDA-approved active Small molecule

This combination drug reduces nasal congestion via pseudoephedrine's sympathomimetic action and alleviates pain and fever via paracetamol's analgesic and antipyretic effects.

This combination drug reduces nasal congestion via pseudoephedrine's sympathomimetic action and alleviates pain and fever via paracetamol's analgesic and antipyretic effects. Used for Symptomatic relief of nasal congestion, headache, and fever associated with common cold and influenza.

At a glance

Generic namePseudoephedrine/Paracetamol
Also known asSinutab
SponsorMcNeil AB
Drug classDecongestant/analgesic combination
TargetAlpha-1 adrenergic receptor (pseudoephedrine); COX inhibition (paracetamol)
ModalitySmall molecule
Therapeutic areaCold and Flu Symptom Relief
PhaseFDA-approved

Mechanism of action

Pseudoephedrine is an alpha-1 adrenergic agonist that constricts blood vessels in the nasal mucosa, reducing swelling and congestion. Paracetamol (acetaminophen) inhibits prostaglandin synthesis in the central nervous system, reducing pain perception and lowering fever set point. Together, they provide symptomatic relief of cold and flu symptoms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: